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miR-221&222Amajor obstacle to successful treatment of hepatocellular carcinoma (HCC) is its high resistance to cytotoxic che-
motherapy due to overexpression of multidrug resistance genes. Activation of the AKT pathway is known to be
involved in chemoresistance inHCC; however, the underlyingmechanismsmodulating the AKT pathway by che-
mopreventive agents remain unclear. In the present study, we found that indole-3-carbinol (I3C) treatment for
tumor cells repressed the AKT pathway by increasing the expression of phosphatase and tensin homolog
(PTEN) in HCC xenograft tumor and HCC cell lines. qRT-PCR data showed that the expression of miR-21 and
miR-221&222 was signiﬁcantly reduced by I3C in HCC cells in vitro and in vivo. Reactivation of the AKT pathway
via restoration of miR-21 was reversed by I3C. Ectopic expression of miR-21 mediated-accelerated wound
healingwas abrogated by I3C.Moreover, reducing the expression ofmiR-21 by anti-miR decreased the resistance
of HCC cells to I3C. These results provide experimental evidences that I3C could function as a miR-21 regulator,
leading to repression of the PTEN/AKT pathway and opening a new avenue for eradication of drug-resistant
cells, thus potentially helping to improve the therapeutic outcome in patients diagnosed with HCC.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Liver cancer, primarily hepatocellular carcinoma (HCC), is the third
leading cause of cancer death worldwide [1,2]. HCC has strikingly in-
creased in the U.S. over the past several years, reaching an incidence
rate of 30,000 new cases each year and is about twice as common in
men than in women. HCC is often diagnosed at late-stage when it is in-
eligible for potentially curative surgical therapies [3]. Moreover, intrin-
sic resistance to chemotherapeutic agents contributes to the low
efﬁcacy of current therapeutic regimens for this cancer type [4]. Many
molecular alterations, known to be involved in the malignant transfor-
mation and progression, may also be responsible for tumor drug resis-
tance [5]. Among various molecular defects that help HCC cells evade
drug-induced apoptosis signaling, constitutive activation of AKT has
drawn much attention [6–8]. Activation of the AKT signaling pathway
has been reported inmore than 40% of human hepatocellular carcinoma
[7,8]. Cell proliferation and survival regulated by the AKT pathway playsest 18th Ave., The Ohio State
fax: +1 614 292 3769.a critical role inmetastasis, thus,making it a potential therapeutic target
to combat metastasis.
The chemopreventive potential of indole-3-carbinol (I3C) (Fig. 1A),
a naturally occurring phytochemical in cruciferous vegetables [9], is
promising due to its unique ability to perturbmany oncogenic signaling
pathways [10–12]. Research on themechanisms bywhich consumption
of indole-3-carbinol might inﬂuence cancer incidence has mainly fo-
cused on its ability to alter estrogenmetabolism. Meanwhile, increasing
evidence shows that I3C arrests cell growth and induces apoptosis by
targeting a broad range of signaling pathways pertinent to cell prolifer-
ation, survival, apoptosis [13] and [14] cell cycle regulation [15]. Al-
though clinical trials of I3C have been mostly conducted with
estrogen-associated cancers such as prostate [10] cervical dysplasia
[16], vulvar intraepithelial neoplasia [17] and breast cancer [18], the
precise molecular mechanism(s) by which I3C exerts its inhibitory ef-
fects on other cancers such as in lung and liver has not been fully
elucidated.
MicroRNAs (miRNAs), a class of highly conserved small non-coding
RNAs of ~22–25 nucleotides, have recently emerged as important regu-
lators of gene expression at the post-transcriptional level by either im-
peding translation or destabilizing target mRNAs [19]. MiRNAs are
involved in crucial biological processes including development,
Fig. 1. I3C inhibits tumorigenic properties of HCC cells in vitro. (A) Chemical structure of I3C. (B, C) I3C reduces HCC cell proliferation in culture. 1 × 104 SK-Hep-1 cells and SNU-449 cells
were seeded in 96-well plates, respectively, and incubated overnight to allow attachment before starting the treatments with DMSO alone or different doses of indole-3-carbinol (I3C)
dissolved in DMSO. Cell viability was assessed at indicated time points by MTT. (D) Clonogenic survival of HCC cells decreased when exposed to I3C. 5 × 102 SK-Hep-1 and SNU-449
cells were separately seeded in 6-well plates and allowed to grow for 24 h. The cells were then treated with medium containing 50 and 100 μM of I3C or DMSO. After 2 weeks, HCC
cells were washedwith PBS twice, ﬁxedwith methanol, and then stained with crystal violet and counted. The data are mean± SD values of triplicates from a three representative exper-
iments (D, E) or mean ± SD values from three independent experiments (A, B), respectively (*P b 0.05; **P b 0.01).
245X. Wang et al. / Biochimica et Biophysica Acta 1853 (2015) 244–253differentiation, apoptosis, and proliferation [20,21] through combinato-
rial regulation either a miRNA may have multiple different mRNA
targets or a mRNA target might similarly be targeted by multiple differ-
ent miRNAs. It is well documented that miRNA expressions are
deregulated in almost all human tumors and speciﬁc miRNAs play a
causal role in cancer pathogenesis [19,20]. OncomiRs such as miR-21,
miR-221&222 and miR-181b [22–25] are found to be up-regulated in
liver cancer patients. MiRNA overexpression in tumors may contribute
to tumorigenesis by down-regulating tumor suppressor genes such as
PTEN. Recent studies have shown that natural agents including indole-
3-carbinol [26], isoﬂavone [27] and [28], curcumin [29], 3,3′-
diindolylmethane [27] and resveratrol [30] could alter miRNA expres-
sion proﬁles, leading to the inhibition of cancer cell proliferation, pro-
motion of apoptosis, or enhancement of efﬁcacy of conventional
cancer therapeutics. Therefore, miRNAs have become attractive targets
for liver cancer chemoprevention and chemotherapy.
In this study, we sought to elucidate the roles of I3C in modulating
the PTEN expression and activation of AKT pathway by targeting
miRNAs in human HCC cell lines.
2. Materials and methods
2.1. Reagents
I3C with N98% purity was purchased from Sigma. A 200 mmol/L
stock solution of I3C was prepared in DMSO and stored at −20 °C.
The stock solution was diluted in cell culture medium for desirable con-
centrations. MTT, Tris, glycine, NaCl, SDS and bovine serum albumin
were purchased from Sigma-Aldrich. MEM, RPMI-1640, FBS, 0.4%
trypan blue vital stain, and antibiotic–antimycotic mixturewere obtain-
ed from Invitrogen. Rabbit polyclonal antibodies to STAT3 and mousemonoclonal antibodies against PTEN were obtained from Santa Cruz
Biotechnology. Phospho-AKT (Ser 473), (Thr 308) and phospho-GSK-
3β (Ser9) AKT antibodies were purchased from Cell Signaling Technol-
ogy. Ki67 antibody was purchased from BD Biosciences. Goat anti-
rabbit–horseradish peroxidase (HRP) conjugate and goat anti-mouse
HRP were purchased from Sigma-Aldrich. Anti-miR, miR mimic, PTEN
siRNA and scrambled control RNAs were obtained from Applied
Biosystems Inc. Human HCC cell lines SK-Hep-1 and SNU-449 were ob-
tained from the American Type Culture Collection.
2.2. Cell lines and transfection
The human HCC cell lines, SK-Hep-1 and SNU-449 were cultured in
MEM and RPMI 1640 containing 10% FBS and penicillin–streptomycin,
respectively. The cells were seeded at a density of 3 × 105 cells in a
six-well culture dish. After 24 h, cells were treatedwith various concen-
trations of I3C dissolved in DMSO. Control cells were treated with 0.1%
DMSO alone. Transfection with 100 nM anti-miR-21 or negative control
RNA (Ambion), 100 nM PTEN speciﬁc siRNA and negative control
(Invitrogen) was conducted with Lipofectamine 2000 according to
manufacturer's instructions. Cells plated at 50–60% conﬂuence in 6-
well plates were transfected at 0 and 48 h and then split into two 6-
well plates. On the next day, the cells were either treated with DMSO
or I3C as described above. The cells were harvested by trypsinization,
stained with 0.4% trypan blue, and live and dead cells were counted
using a hemocytometer.
2.3. Western blotting
For detection of phosphoproteins, I3C-treated whole-cell extracts
were lysed in lysis buffer [31]. Lysates were then centrifuged at
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12% SDS-PAGE gel. After electrophoresis, the proteins were blotted
onto a PVDF membrane, blocked with 5% nonfat milk, and probed
with primary antibodies overnight at 4 °C. The blot was washed, ex-
posed to HRP-conjugated secondary antibodies for 1 h, and ﬁnally visu-
alized by a chemiluminescent detection system (Pierce).
2.4. RNA isolation and real-time PCR (qRT-PCR)
Total RNA was extracted using TriZol reagent as recommended by
the manufacturer (Invitrogen). To verify the alterations in the expres-
sion of speciﬁc miRNAs, TaqMan MicroRNA Assay Kit was used. 10 ng
of total RNA from each sample was subjected to reverse transcription
with a speciﬁc miRNA primer. Real-time RT-PCR (qRT-PCR) was then
carried out in a total of 25 μl reaction mixture in an ABI Step One Plus
real time PCR system. The PCR program was initiated by 10 min at
95 °C before 40 thermal cycles, each at 15 s at 95 °C and 1 min at
60 °C. Data were analyzed according to the comparative Ct method
and normalized by U6 expression in each sample [28]. Real-time RT-
PCRwas performed using SYBRGreen as the detection ﬂuorophore. For-
ward (F) and reverse (R) primers usedwere as follows: PTEN-F 5′-CGGC
AGCATCAAATGTTTCAG-3′ and PTEN-R 5′-AACTGGCAGGTAGAAGGCAA
CTC-3′; β-actin-F 5′-CCAAGGCCAACCGCG AGAAGATGAC-3′, and β-
actin-R: 5′-AGGGTACATGGTGGTGCCGCCAGAC-3′.
2.5. Plasmid construct
The 3′-UTR of the human PTEN gene with miR-21 binding site
(PTEN-wt) andmiR-21 binding site deleted (PTEN-del) was PCR ampli-
ﬁed from human genomic DNA (wt: forward, 5′-CCG CTC GAG TTC ACA
TCC TAC CCC TTTGC-3′ and reverse, 5′-ATAAGAATG CGG CCG CGG TCC
AGA GTC CAG CAT AAA-3′; del: forward, 5′-CCG CTC GAG GCA GTT GGC
TAA GAG AGG TT-3′ and reverse, 5′-ATA AGA ATG CGG CCG CGG TCC
AGA GTC CAG CAT AAA-3′), and cloned into the Xho1 and Not1 of
psiCHECK-2-control vector (Promega, Madison, WI, USA), which was
designated psiCHECK-2-PTEN-wt and psiCHECK-2-PTEN-del after
sequencing.
2.6. Luciferase assay
Cells were seeded in 24-well plates 24 h before transfection. SK-
Hep-1 cells were transiently transfected with wild-type (psiCHECK-2-
PTEN-wt) or deletion (psiCHECK-2-PTEN-del) in the presence or ab-
sence of I3C using Lipofectamine 2000. Luciferase assays were per-
formed 48 h post-transfection using the dual-luciferase assay system
(Promega, Madison, WI, USA) and they were normalized for transfec-
tion efﬁciency with cotransfected Renilla luciferase. All experiments
were performed in triplicate.
2.7. Apoptosis assay
For apoptosis assays, ﬂoating and adherent cells were harvested at
24 and 48 h after transfection, and then combined and washed with
PBS. Annexin V in combination with PI (Santa Cruz Biotechnology)
was added to the cells and samples were analyzed within 20 min after
staining by a Beckman Coulter EPICS XL (Beckman Coulter Inc., CA,
USA) t. Fluorescence was detected by ﬂow cytometry. Experiment was
repeated in triplicate.
2.8. Cell colony formation assay
5 × 102 SK-Hep-1 and SNU-449 cells were separately seeded in 6-
well plates and allowed to grow for 24 h. Cells were then treated with
various concentrations of I3C or 0.1% DMSO. After 2 weeks, cells were
washed with phosphate-buffered saline (PBS) twice, ﬁxed with metha-
nol, stained with crystal violet and counted.2.9. MTT assay
The antiproliferative effect of I3C on HCC cells was determined by
theMTT dye uptakemethod [30]. Brieﬂy, the cells (5 × 103/ml)were in-
cubated in triplicate in a 96-well plate in the presence or absence of the
indicated concentration of I3C in a ﬁnal volume of 0.2 ml for different
time intervals at 37 °C. Thereafter, 10 μl of MTT solution (5 mg/ml in
PBS) was added to each well. After a 2 hr incubation period at 37 °C,
0.1 ml lysis buffer (20% SDS, 50% dimethylformamide) was added
followed by an additional 1 hr incubation at 37 °C, and then the optical
density (OD) at 570 nm was measured by Tecan plate reader within
5 min.
2.10. Wound healing assay
For wound healing assay, SK-Hep-1 cells were seeded at a density of
3 × 105 cells in a six-well culture dish. After 24 h, cells were transfected
with anti-miR-21, PTEN speciﬁc siRNA or respective negative control
RNA alongwith the indicated concentration of I3C or DMSOwere plated
after 24 h post-transfection. A scratchwoundwas inﬂicted diagonally in
the monolayer with a pipette tip. Image of the wound was captured at
the beginning and every 24 h under the microscope.
2.11. PIP3 ELISA assay
PIP3 ELISA mass Elisa (Echelon Biosciences, Inc.) was used to deter-
mine the relative amount of PIP3 present in untreated and 200 μm I3C
treated cells at indicated time. Brieﬂy, lipids were extracted from cells
and the PIP3 analysis was carried out as described in themanufacturer's
instructions, with the colorimetric signal measured at 450 nm using
Tecan plate reader.
2.12. HCC xenograft study
Female athymic nude mice (5–7 weeks of age, from Harlan Labora-
tory) were used for investigating the antitumor efﬁcacy in vivo. All ex-
perimental procedures using mice were done in accordance with
protocols approved by The Ohio State University Institutional Animal
Care and Use Committee. Brieﬂy, approximately 5 × 106 SK-Hep-1
cells were injected subcutaneously into the right ﬂanks of the nude
mice. When tumors reached ~50 mm3, mice were randomly divided
into two treatment groups (n = 7) that received the following treat-
ment twice by I. P. per week: 1) I3C at 25 mg/kg body weight or 2) 1%
DMSO in PBS. Tumor volumes were calculated as ab2 / 2 (where a is
the longest diameter and b is the shortest diameter) [10]. The mice
were sacriﬁced after 4 weeks of treatment. On sacriﬁce, tumor tissue
from each mouse was harvested and cut into two pieces: one part was
snap-frozen in liquid nitrogen for molecular analysis and the other
part was ﬁxed in formalin and embedded in parafﬁn for immunohisto-
chemical staining.
2.13. Histological evaluations
Formalin-ﬁxed tumor sections (4 μm) were immunostained with
antibodies against Ki67 [32]. The percentage of Ki67-positive tumor
cells was counted in 10 randomly chosen ﬁelds (~400 cells) from repre-
sentative tumor samples from each experimental group. Tumor tissues
were also stainedwith hematoxylin and eosin (H&E) by standard proce-
dures and examined microscopically.
2.14. Statistics
Experiments were repeated three times, each performed in tripli-
cate, and the data were presented as mean ± S.D. Statistical analysis
of the data was performed using Student's t-test. P b 0.05 was consid-
ered signiﬁcant.
Fig. 2. I3C inhibits PTEN/AKT signaling. (A) Inhibition of the PTEN/AKT signaling axis by indole-3-carbinol in HCC cells.Western blot analysis of the time-dependent effects of I3C on phos-
phorylation of AKT and its downstream targets GSK3β in SK-Hep-1 and SNU-449 cells exposure to 200 μM I3C in 10% FBS-containingDMEM. (B) Using a competitive PIP3 ELISA kit, level of
PIP3 in cells untreated or treatedwith 200 μMof I3C at indicated time was examined. (C) Real-time analysis of the time-dependent effects of I3C on the expression levels of miR-21, miR-
221&222 in SK-Hep-1 and SNU-449 cells exposed to 200 μM I3C in 10% FBS-containing DMEM (*P b 0.05; **P b 0.01).
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3.1. I3C inhibits proliferation of SK-Hep-1 and SNU-449 cells
I3C is produced by the breakdown of the glucosinolate glucobrass-
icin, which can be found at relatively high levels in cruciferous vegeta-
bles [9]. The antiproliferation effects of I3C have been assessed in
various human cancers [10,12–18]. To demonstrate the broad
antiproliferation effects on different liver cancer cells,we used the hepa-
tocellular carcinoma cell lines SK-Hep-1 and SUN-449 to examine the
effects of I3C on cell proliferation. For a short term study, SK-Hep-1
and SNU-449 cells were treated with DMSO or 50, 100, 150 and
200 μM I3C dissolved in DMSO (ﬁnal concentration of 0.1%) for 24 and
48 h, respectively, and then subjected to the MTT assay. As shown in
Fig. 1B and C, both cell lines were to the antiproliferative effect of I3C
in a dose- and time-dependent manner. SNU-449 cell proliferation
was inhibited up to 50% by I3C after a 48 hr treatment at 200 μM I3C
(Fig. 1C). Similarly, clonogenic survival of HCC cells was signiﬁcantly re-
duced in a dose dependent manner when treated with I3C at 50 and
100 μM for 2 weeks (Fig. 1D and E). Moreover, the size of the colonies
was markedly smaller in drug-treated cell cultures. Thus, I3C inhibits
both growth and clonogenic survival of HCC cells. I3C has been reported
to induce apoptosis and cell cycle arrest inmany human cancers such as
prostate cancer (10,12,15), breast cancer (11) and myeloid and leuke-
mia cells (14). However, to date, a limited number of study focused on
hepatocellular carcinoma. To evaluate the role of apoptosis in the
growth-inhibitory effects of I3C, we then characterized the apoptoticcell death induced by I3C. We stained the cells with Annexin V-FITC
and the PI dye, and then analyzed the cells by ﬂow cytometry after I3C
treatment. Representative results are shown in Fig. S1. After 200 μM
I3C treatment, the frequency of apoptotic cells markedly increased to
10.92% (24 h), 27.42% (48 h) and 21.42% (48 h) for SNU-449 and SK-
Hep-1 cells, respectively. Quantitative assessment of the percentage of
Annexin V-positive cells from 3 independent experiments showed
that apoptotic cell death was signiﬁcantly increased by I3C treatment
in HCC cell lines (Fig. S1B). These ﬁndings agree with previous studies
on I3C-induced apoptosis in other cancers.
3.2. I3C targets the PTEN/AKT signaling pathway and downregulates miR-
21, miR-221&222
It has been reported previously that I3C inhibits growth of many
types of cancer cells in culture by targeting the AKT signaling pathway,
which is activated in response to growth factor stimuli [33]. The proto-
oncogene product AKT plays amajor role in the cell survival pathway by
regulating cell growth and apoptosis. Activation of the AKT signaling
pathway is known to initiate from membrane-bound receptors via
PI3K and subsequent phosphorylation of downstream signaling targets
(e.g. GSK3β), inducing its inactivation and, in turn, inhibiting apoptosis
in response to growth factor stimuli.
In this study, we investigated whether activation of the AKT protein
was altered in I3C-treated SK-Hep-1 and SNU-449 cells. HCC cell lines
treated with I3C did not show any changes at the steady-state levels
of total AKT protein, whereas phosphorylations at serine 473 and
Fig. 3. Inhibitory effect of I3C onmiR21- activated PTEN/AKT pathway. (A) I3C abrogated upregulation ofmiR-21 inHCC cells. HCC cells transfectedwith 100nMmiR-21 or negative control
were exposed to 200 μM I3C for 48 h. (B)miR-21mediated activation of PTEN/AKT pathwaywas reversed by I3C. HCC cells transfectedwithmiR-21 or negative control were treatedwith
DMSO or 200 μM I3C for 48h and subjected toWestern blot analysis. (C) I3C enhanceddownregulation ofmiR-21mediated by anti-miR-21 inHCC cells. HCC cells transfectedwith 100 nM
anti-miR-21 or negative control were exposed to 200 μM I3C for 48 h. (D) anti-miR-21 mediated inhibition of PTEN/AKT pathway was enhanced by I3C. HCC cells transfected with anti-
miR-21 or negative control were treatedwith DMSO or 200 μM I3C for 48 h and subjected toWestern blot analysis. (E) The wt or del reporter plasmidwas transfected into SK-Hep-1 cells
with I3C (I3C+) or without I3C (I3C−). The normalized luciferase activity in the control group was set as relative luciferase activity. Luciferase activity of psiCHECK-2-PTEN-wt was sig-
niﬁcantly decreased compared with vector control in the absence of I3C (***P b 0.001). In the presence of I3C, decreased luciferase activity of psiCHECK-2-PTEN-wt was abrogated. Lucif-
erase activity of psiCHECK-2-PTEN-delwas not affected by I3C. The data are representative of three independent experiments. (F) Acceleratedwoundhealing causedby ectopic expression
of miR-21 was reversed by I3C. HCC cells transfected with miR-21 were treated with DMSO or 200 μM for 48 h, and subjected to migration analysis. Results are representative of at least
three independent experiments.
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by I3C (Fig. 2A). The dose–response effect on phosphorylation for the
key downstream target, GSK-3β, was observed in both cell lines. No sig-
niﬁcant change was found in total GSK-3 level. The basal level of PTEN,
which acts as an inhibitor of the AKTpathway, was slightly detectable in
both cell lines. Interestingly, PTEN expression increased signiﬁcantly
with prolonged time of I3C treatment both in cultured SK-Hep-1 and
SNU-449 cells. To conﬁrm these results, qRT-PCR analysis of PTEN
from DMSO-treated cells or DMSO plus I3C-treated cells revealed
PTEN mRNA level was signiﬁcantly up-regulated in I3C-treated cells
versus DMSO-treated mice (Fig. S2). The change of PTEN mRNA is con-
sistent with the alterations in the protein level. PTEN counterbalances
PI3K mediated generation of phosphatidylinositol (3–5)-trisphosphate
(PIP3) and hence the level of AKT phosphorylation at ser 473 and thr
308. To demonstrate that I3C abrogated the production of PIP3, the cel-
lular content of PIP3 was quantiﬁed using a PIP3-competitive ELISA.We
conﬁrmed that the amount of PIP3 in the SK-Hep-1 and SNU-449 cell
lines was gradually downregulated post treatment by I3C at 24 h and
48 h, respectively (Fig. 2B).PTEN was shown to be a direct target of miR-21 and contributes to
miR-21-induced cell invasion [34]. Previous studies also demonstrated
that miR-221&222 enhanced cellular migration through the activation
of the AKT pathway and metallopeptidases by targeting PTEN and
TIMP3 tumor suppressors [23]. Moreover, miR-21 and miR-221&222
were reported to highly overexpress in primary HCC tissues and cell
lines [23,34]. Inhibition of miR-21 in cultured HCC cells increased the
expression of PTEN tumor suppressor and decreased tumor cell prolifer-
ation, migration, and invasion. To examine whether miRNAs are in-
volved in I3C-induced PTEN up-regulation, we compared the
expression proﬁles of miR-21, miR-221&222 in cells treated with I3C
and DMSO. The expression levels of thesemiRNAs were signiﬁcantly al-
tered by I3C in both SK-Hep-1 and SUN-449 cells. Compared with cells
treated with DMSO, down-regulation of miR-21, miR-221&222 reached
38%, 27%, and 32% in SK-Hep-1 cells (Fig. 2C, left), respectively. This re-
duction was also obvious in SNU-449 cells with a similar trend (Fig. 2C,
right), which was consistent with the aforementioned results of cell
proliferation inhibition. Altogether, these ﬁndings suggest that PTEN
up-regulation could be potentially modulated by I3C activity.
Fig. 3 (continued).
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To further investigate whether miRNA-mediated regulation of the
PTEN/AKT pathway was affected by I3C, SK-Hep-1 cells were
transfected with miR-21 and anti-miR21 respectively, and further ex-
posed to I3C for 48 h. Transfection of miR-21 elevated the miR-21
level and decreased PTEN protein accompanied by increased phospho-
AKT at Ser473 and Thr308 and phospo-GSK-3β at Ser9 (Fig. 3A and B).
Exposure to I3C declined themiR-21 expression by 20% and partially re-
stored PTEN. Consequently, the miR-21-activated AKT pathway was
inhibited by I3C (Fig. 3B). In contrast, depletion of miR-21 by anti-
miR-21 in SK-Hep-1 cells signiﬁcantly reduced the phosphorylation of
AKT, downstream targets of PTEN, that are key mediators of tumor cell
survival (Fig. 3C and D). Cells transfected with anti-miR-21 exposed to
I3C show much lower miR-21 expression and higher PTEN expression
followed by lower phosphorylation of AKT (Fig. 3C and D). Clearly,
miR-21 is involved in the I3C-induced inhibition of the PTEN/AKT path-
way. To study whether I3C induced downregulation of miR-21 directly
regulates PTEN, we cloned 3′UTR of PTENwith or withoutmiR-21 bind-
ing site (PTEN-wt and PTEN-del) to psiCHECK-2 vector and performed a
luciferase assay. As shown in Fig. 3E, luciferase activity of psiCHECK-2-
PTEN-wt was signiﬁcantly decreased compared to the vector control
in the absence of I3C, thus suggesting PTEN is a direct target of miR-21(***P b 0.001) which is consistent with previous ﬁndings (34). In the
presence of I3C, decreased luciferase activity of psiCHECK-2-PTEN-wt
was abrogated, and this could be due to I3C-induced miR-21 inhibition
(Fig. 2B). As expected, luciferase activity of psiCHECK-2-PTEN-del was
not affected by I3C. These results conﬁrmed that I3C induced downreg-
ulation of miR-21 directly regulates PTEN. Cells treated with miR-
221&222 or anti-miR-221&222, along with I3C did not show obvious
change of PTEN/AKT pathway compared to cells treated with miR-
221&222 or anti-miR-221&222 alone, which suggested that miR-
221&222 may not be involved in inhibition of PTEN/AKT pathway by
I3C (data not shown).
To further conﬁrm the above results, wound healing assay was con-
ductedwith cells transfectedwithmiR-21, anti-miR-21 or negative con-
trol RNA and cultured in medium containing DMSO or 200 μM I3C, and
monitored to assess wound healing after 48 h (Fig. 3F). The rate of
wound healing of cells transfected with miR-21 was accelerated com-
pared with cells treated with the respective control. Accelerated
wound healing was inhibited markedly by I3C indicating that I3C can
abolish wound healing in miR-21-overexpressing cells. Conversely,
anti-miR-21 decreased wound healing rate in SK-Hep-1 cells with I3C
exposure further enhancing this effect. This result was further con-
ﬁrmed by the slow wound healing rate inhibited by both anti-miR-21
and I3C.
Fig. 4. Inhibition ofmiR-21, miR-221&222 reduces resistance of HCC cells to I3C. (A, B)MTT assay of HCC cells in the presence of I3C. SK-Hep-1 cells seeded in 96-well plateswith a density
of 1 × 104 cells/well were treated with anti-miR-21, anti-miR-221&222 or miR-21, miR-221&222 mimic. After 48 h, I3C was added at various concentrations (0–200 μM) and cells were
allowed to grow for another 48 h followed by MTT assay. The absorbance at 595 nm of treated cells was divided by that of the untreated cells (which was taken as 100%) to assess the
percentage of growth, which was then plotted as a function of the I3C concentration (*P b 0.05; **P b 0.01).
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The refractoriness of cancer cells to chemotherapy continues to be a
major clinical obstacle for successful treatment of a number of cancers
including liver cancer. Recently, there has been considerable interest
in the potential use of anti-miR oligos as anticancer agents for HCCs be-
cause of their preferential accumulation in the liver [35]. As shown in
Fig. 4A, the survival rate of SK-Hep-1 cells treated with anti-miR-21 sig-
niﬁcantly decreased when exposed to I3C at concentrations ranging
from 50 to 200 μM. miR-21 expression was reduced by 81% in HCC
cells transfectedwith anti-miR-21,whichwas further reduced by an ad-
ditional 10% upon exposure to I3C (Fig. 4A). In contrast, ectopic expres-
sion of miR-21 to SK-Hep-1 cells decreased sensitivity to I3C (Fig. 4B).
These data indicate that anti-miR-21 can sensitize HCC cells to I3C. We
also examined whether miR-221&222 have similar effect on SK-Hep-1
cell to I3C. As expected, miR-221&222 did not enhance the sensitivity
of SK-Hep-1 cells to I3C (Fig. 4 A and B), which further conﬁrm the re-
sults that no obvious changes of PTEN/AKT pathway were observed be-
tween cells treatedwithmiR-221&222 or anti-miR-221&222 alongwith
I3C and cells treated with miR-221&222 or anti-miR-221&222 alone.3.5. I3C suppresses the growth of HCC xenograft tumors in vivo
To assess the inhibition of I3C on HCC growth in vivo, SK-Hep-1 cells
were used to generate xenograft tumors in athymic nudemice. Athymic
nude mice bearing established subcutaneous SK-Hep-1 tumors around
50mm3were treatedwith I3C twice aweek at 25 mg/kg by I.P. injectionfor onemonth (n=6). As shown in Fig. 5, the tumor sizemeasured by a
caliper demonstrated signiﬁcant inhibition of SK-Hep-1 tumor growth
as early as 9 days after the ﬁrst injection of I3C. Notably, I3C treatment
inhibited tumor size by 50% and weight by 60%, respectively, relative
to vehicle-treated controls (P b 0.01) (Fig. 5B and C).
3.6. I3C inhibited PTEN/AKT pathway in vivo
We next sought to investigate whether the tumor-suppressive
mechanism of I3C identiﬁed in vitro also occurs in vivo by evaluating
representative intratumoral biomarkers (e.g. PTEN/AKT pathways)
and miR-21, miR-221&222. Real time PCR analysis indicated miR-21,
miR-221&222 were down-regulated by I3C up to 40% in SK-Hep-1 xe-
nograft tumors (Fig. 6A). Importantly, relative to theDMSO-treated con-
trols, PTEN was markedly increased in the tumors treated with I3C, and
accompanied reduction of AKT phosphorylation at Ser 473 and Thr 308
and the levels of p-GSK (Ser 9) (Fig. 6B) which represent hallmark bio-
markers of I3C-induced inhibition of PTEN/AKT. Moreover, the suppres-
sion of SK-Hep-1 tumor growth by I3C was reﬂected in a signiﬁcant
reduction in the number of proliferating cells in the tumor, as deter-
mined byKi67 immunostaining (Fig. 6C andD). In summary, these ﬁnd-
ings suggest that I3C inhibited PTEN/AKT pathway, simultaneously
down-regulated miR-21, miR-221&222 in vivo.
4. Discussion
Despite rapid progress in detection and therapy, advanced HCC still
remains a major clinical problem due to the drug resistance. Seeking
Fig. 5. I3C suppresses tumor growth in nude mice. Athymic nude mice bearing SK-hep-1
xenograft tumorswere treatedwith I3C at 25 mg/kg twice aweek. (A) Photos of represen-
tative xenograft tumors harvested at the end of the treatment. (B) Suppressive effect of I3C
on the growth of established SK-Hep-1 xenograft tumors in nude mice relative to that in
vehicle-treated controls (n = 7). (C) Statistical analysis of tumor weight (*P b 0.05;
**P b 0.01).
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long-term goal to improve the therapeutic efﬁcacy. HCC exhibits alter-
ations in the abundance of speciﬁc miRNAs with oncogenic and tumor
suppressor activities [23,36–38]. The relationship between aberrant
miRNA expression and HCC development indicates that miRNAs could
be the potential targets for chemopreventive and chemotherapeutic
agents. Accordingly, miR-21 and miR-221&222 are the most frequently
up-regulated microRNAs associated with cancer development, includ-
ing liver [23,34], lung [23], glial [24], and colorectal cancer [22]. It has
been shown that inhibition of miR-21 by anti-oligos decreased tumor
cell proliferation,migration, and invasion in culturedHCC cells via an in-
crease in PTEN expression and downstream events involving AKT phos-
phorylation [34]. Moreover, miR-221&222 was reported to induce
TRAIL resistance and enhance cellular migration through the activation
of the AKT pathway by targeting PTEN. The tumor suppressor PTEN reg-
ulates the PI3K/AKT, a major cell survival pathway that plays a key role
in the development of drug resistance, including TRAIL [23]. Thus, we
studied the role of miR-21, miR-221&222 in I3C induced growth inhibi-
tion in HCC cells.
In this study,we found that expression ofmiR-21,miR-221&222was
signiﬁcantly down-regulated by the chemopreventive drug I3C in vitro
and in HCC xenograft tumors (Figs. 1 and 6). Moreover, ectopic expres-
sion of miR-21 mediated down-regulation of PTEN and activation of
AKT/GSK and abrogated I3C-induced wound healing reduction. Asexpected, depletion of miR-21 by anti-miR-21 along with exposure to
I3C signiﬁcantly increased PTEN, inhibited AKT/GSK pathway and po-
tentiated I3C-induced wound healing reduction. In the presence of
I3C, decreased luciferase activity of psiCHECK-2-PTEN-wt was abrogat-
ed and this may be due to I3C-induced miR-21 inhibiton (Fig. 3E)
which further conﬁrmed that I3C induced down-regulation of miR-21
directly regulates PTEN. These results suggested the combination of
I3C and anti-miR-21 treatment has a synergetic effect on inhibition of
PTEN/AKT pathway respectively relative to either depletion of miR-21
or exposure to I3C alone. These ﬁndings suggested that HCC growth in-
hibition caused by I3C could bemediated, at least in part, bymodulating
miR-21 and its targets. Our data are in accordance with the results re-
ported by other researchers [13,16]. Omar et al. has shown the down-
regulation of AKT and up-regulation of downstream factors such as
phosphorylated GSK, CCND1 and C-MYC during HCC development and
reversion of the effects by chemopreventive agents, [1-(4-Chloro-3-
nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), an I3C de-
rivative in a mouse model of hepatocellular carcinoma [13]. Similarly,
I3C administration up-regulated the PTEN expression by reducing the
expression of miR-21 in vinyl carbamate-induced lung cancer model
[26]. In contrast, it has been reported that DIM, a primary I3C derivative,
signiﬁcantly reduces cell proliferation of human breast cancer cells via
up-regulation miR-21, which subsequently down-regulated CDC25A
[39]. These ﬁndings indicate that miR-21 functions as a pleiotropic
oncomiR in cancer development either by reducing the expression of
tumor suppressors such as PTEN [26] or oncogenes such as CDC25A
[39]. Mounting evidence indicates that the role of miRNAs in carcino-
genesis appears to be complicated, in the sense that both oncogenic
and tumor suppressive effects were reported in different cancers. The
expression level ofmiR-221&222 altered in I3C-treated cell lines and tu-
mors suggest that these two microRNAs might also contribute to the
I3C-induced reduction of PTEN. However, combination of either
ecotopic expression of miR-221&222 or depletion of miR-221&222
with I3C treatment did not show signiﬁcant change on PTEN and AKT/
GSK pathway compared with single treatment. Importantly, exogenous
delivery of miR-21, miR-221&222 enhanced resistance of HCC to I3C
and inhibition of miR-21, miR-221&222 inversely decreased HCC sensi-
tivity to I3C. These results indicated that miR-221&222 are involved in
the I3C inducedHCC tumorigenic property inhibition but not by regulat-
ing PTEN and AKT/GSK pathway. In contrast, combined treatment with
miR-21 and I3C contributes to reduced HCC tumorigenicity by activat-
ing PTEN and inhibiting AKT/GSK pathway. Taken together, by deﬁni-
tion of a sensitivity enhancer for cancer therapy, the given miRNAs
themselves (at certain expression levels) may not have any, or have
only minor effects on cancer cell proliferation, apoptosis, or cell cycle;
however, in combination with another treatment, additive or synergis-
tic effects can be observed. This effect of miRNAs provides a novel plat-
form for targeting resistant cancer cells.5. Conclusions
In summary, to the best of our knowledge this is the ﬁrst report on
the down-regulation of miR-21 by the chemopreventive drug I3C in a
HCC xenograft model and HCC cell culture, and this can explain inhibi-
tion of the PTEN/AKT pathway induced by I3C. Our ﬁndings could be
used to examine the efﬁcacy of chemopreventive agents and themech-
anisms through which chemopreventive agents inhibit carcinogenesis.
Another potential use of miRNAs in cancer chemoprevention is to
detect and monitor the toxic effects of chemopreventive agents. Our
results clearly demonstrate that speciﬁc targeting of miRNAs by I3C
could open a new avenue for eradication of drug-resistant cells, thus
potentially improving survival outcome in patients diagnosed with
malignancies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.10.017.
Fig. 6. The inhibitory effect of I3C on PTEN/AKT pathway in vivo is mediated partly through miR-21, miR-221&222. (A) Real-time PCR analysis of miR-21, miR-221&222 expressions in
tumors. (B) Western blot analysis of PTEN/AKT pathway in tumors developed in mice treated with I3C. (C) Photographs of H&E-stained sections of tumors formed in nude mice treated
as indicated (top) and representative Ki67-immunostained tumor sections. (D) Proliferation indices of SK-Hep-1 tumors from each treatment group, as determined by the percentage of
Ki67-positive cells in representative tumor samples (n = 3).
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